Abstract: A system for providing navigation services to a user in a volume of space can include a user device disposed in the volume of space, where the user device broadcasts, at a first time, at least one first communication signal into the volume of space, where the at least one first communication signal includes a first identification of the user and a destination of the user. The system can also include multiple electrical devices disposed in the volume of space, where each electrical device includes a transceiver, where the transceiver of a first subset of the electrical devices receives the at least one first communication signal broadcast by the user device, where the first subset of electrical devices sends a second communication signal based on the at least one first communication signal. The system can further include a controller communicably coupled to the plurality of electrical devices.

Abstract: A system for providing navigation services to a user in a volume of space can include a user device disposed in the volume of space, where the user device broadcasts, at a first time, at least one first communication signal into the volume of space, where the at least one first communication signal includes a first identification of the user and a destination of the user. The system can also include multiple electrical devices disposed in the volume of space, where each electrical device includes a transceiver, where the transceiver of a first subset of the electrical devices receives the at least one first communication signal broadcast by the user device, where the first subset of electrical devices sends a second communication signal based on the at least one first communication signal. The system can further include a controller communicably coupled to the plurality of electrical devices.

Abstract: This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.

Abstract: This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.

Abstract: This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.

Abstract: This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.

Abstract: This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.

Abstract: Parenteral formulations of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl) -2-methylpropionic acid (CCI-779) are provided. One parenteral formulation contains CCI-779, an alcoholic co-solvent, and an antioxidant. Another parenteral formulation contains CCI-779, an alcoholic solvent, an antioxidant, a diluent solvent, and a surfactant. Processes for preparing parenteral CCI-779 formulations using a co-solvent concentrate are also provided.

Abstract: A method of preparing a rapamycin composition having increased potency is provided. The method involves selecting a rapamycin compound having less than 1.5% oxidative and hydrolytic rapamycin impurities and formulating the selected rapamycin with an antioxidant and optional excipients.

Abstract: The present disclosure is directed to combination therapies of tigecycline and heparin and methods of administration of tigecycline and heparin.

Abstract: This invention provides parenteral formulations of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779).